login
  Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Gender does not affect periprocedural complications or long-term results of catheter ablation


Wednesday, 05 Oct 2011 10:50
Sonia Ammar
Sonia Ammar


A study presented at the European Heart Rhythm Association (EHRA)-Europace conference (26–29 June, Madrid) shows that gender does not affect periprocedural complications or outcomes of catheter ablation for paroxysmal atrial fibrillation.

 


Investigators Ammar et al found that there was no significant differences between men and women in the incidence of periprocedural stroke and transient ischaemic attack (1.8 vs. 0.9%; p=0.35), tamponade (3.6 vs. 1.5%; p=0.12), severe haematoma (1.8 vs. 0.9%; p=0.3), pseudoaneurysm (0.6 vs. 0.6%; p=ns) or pulmonary vein stenosis (0.6 vs. 0.3; p=ns). Additionally, after a mean follow-up of 3.4±2.7 years, 51% of women and 55% of men were free from atrial arrhythmias without antiarrhythmic drugs (p=0.34).

 

The results of the new study are in contrast to previous studies, which have shown that women have more frequently persistent atrial fibrillation, complications and procedural failures than men. However, the lead investigator of the new study, Sonia Ammar, German Heart Center, Hospital rechts der Isar at the Technical University of Munich, said that her study may have had a more homogeneous population than had previous studies (which possibly explained why no differences in outcomes were observed between men and women). She explained that in her study, the duration of atrial fibrillation before ablation was about six years in both men and women and, unlike other studies, women were not referred later for catheter ablation despite being significantly older than men (61±9 years vs. 55±10 years). “In regard to acute complications, there was a tendency toward more tamponades in women without a statistical difference. It is important to say that we reported our experience [of catheter ablation] since 1998. In the early years, complications of catheter ablation for atrial fibrillation were more frequent. In the last few years, we had an incidence of tamponades of less than 1% in paroxysmal atrial fibrillation ablation. Therefore, the difference is disappearing.” According to Ammar, some specificities of the German population in the study may also have affected the result.

 

The women in her study, as well as being older, had a higher CHADS2 (Congestive heart failure, hypertension, age ≥75 years, and prior stroke) score but this baseline characteristic did not appear to significantly increase the incidence of stroke in women compared with men (2.4% vs. 3.5%). “Eighty seven per cent of strokes occurred in patients with atrial fibrillation recurrence and/or no adequate oral anticoagulation. Atrial fibrillation ablation seems to modify the course of the disease and the rate of stroke, particularly in women.”

 

Although gender does not appear to have a significant effect, according to this study at least, on the outcome of catheter ablation, it does significantly influence the pathophysiology, epidemiology, and clinical presentation of many cardiac arrhythmias. Ammar said: “Women have significantly longer QT intervals than men, despite having higher heart rates. In contrast, men have a higher incidence of atrial fibrillation, Brugada syndrome, early repolarisation syndrome and sudden death compared with women.” Additionally, as women have a greater risk of drug-induced QT prolongation, antiarrhythmic drugs have to be “prescribed very carefully” in women. Ammar concluded: “Differences in gender hormones may explain some of these findings, but the reasons for these gender differences are not completely understood.” 




Add New Comment

Related Items


Most popular


St Jude Medical completes acquisition of CardioMEMS
Monday, 02 Jun 2014
St Jude Medical has announced it has completed its acquisition of privately held CardioMEMS, developer of the CardioMEMS heart failure system. The acquisition was completed on 30 May 2014. St Jude Medical completes acquisition of CardioMEMS

FDA approves CardioMEMS heart failure system
Monday, 02 Jun 2014
The US Food and Drug Administration has approved the CardioMEMS heart failure system that measures the pulmonary artery pressures and heart rates of patients with New York Heart Association (NYHA) C... FDA approves CardioMEMS heart failure system

Wearable defibrillator registry (WEARIT-II) update
Monday, 23 Jun 2014
At Cardiostim/EHRA Europace (18–21 June, Nice, France), Ilan Goldenberg presented an update on one-year follow-up results from the prospective WEARIT-II registry of 1,404 patients using the Lifevest ... Wearable defibrillator registry (WEARIT-II) update

Features


What is the best strategy for managing atrial fibrillation?
Monday, 14 Jul 2014
John D Day, president-elect of the Heart Rhythm Society writes that many cases of atrial fibrillation in the USA could be prevented or reversed with lifestyles focussed on health. What is the best strategy for managing atrial fibrillation?

Defibrillation testing: End of an era, or pause for thought?
Monday, 23 Jun 2014
The need to perform defibrillation testing at the time of implantable cardioverter defibrillator (ICD) surgery has been the focus of significant discussion and debate over the past years. A number of ... Defibrillation testing: End of an era, or pause for thought?

Profiles


Nick Linker
Monday, 14 Jul 2014
Nick Linker is president-elect of the British Heart Rhythm Society (BHRS) and programme director of ... Nick Linker

Richard Fogel
Thursday, 08 May 2014
Richard Fogel, president-elect of the Heart Rhythm Society and chief executive officer at St V... Richard Fogel

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
 
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions